Toward gene therapy for hemophilia A with novel adenoviral vectors: successes and limitations in canine models

被引：12

作者：

Arruda, VR ^{[1
]}

机构：

[1] Univ Penn, Childrens Hosp Philadelphia, Sch Med, Dept Pediat, Philadelphia, PA 19104 USA

来源：

JOURNAL OF THROMBOSIS AND HAEMOSTASIS | 2006年 / 4卷 / 06期

关键词：

D O I：

10.1111/j.1538-7836.2006.01964.x

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：1215 / 1217

页数：3

共 16 条

[1] FACTOR-VIII GENE INVERSIONS IN SEVERE HEMOPHILIA-A - RESULTS OF AN INTERNATIONAL CONSORTIUM STUDY
ANTONARAKIS, SE
ROSSITER, JP
YOUNG, M
HORST, J
DEMOERLOOSE, P
SOMMER, SS
KETTERLING, RP
KAZAZIAN, HH
NEGRIER, C
VINCIGUERRA, C
GITSCHIER, J
GOOSSENS, M
GIRODON, E
GHANEM, N
PLASSA, F
LAVERGNE, JM
VIDAUD, M
COSTA, JM
LAURIAN, Y
LIN, SW
LIN, SR
SHEN, MC
LILLICRAP, D
TAYLOR, SAM
WINDSOR, S
VALLEIX, SV
NAFA, K
SULTAN, Y
DELPECH, M
VNENCAKJONES, CL
PHILLIPS, JA
LJUNG, RCR
KOUMBARELIS, E
GIALERAKI, A
MANDALAKI, T
JENKINS, PV
COLLINS, PW
PASI, KJ
GOODEVE, A
PEAKE, I
PRESTON, FE
SCHWARTZ, M
SCHEIBEL, E
INGERSLEV, J
COOPER, DN
MILLAR, DS
KAKKAR, VV
GIANNELLI, F
NAYLOR, JA
TIZZANO, EF
[J]. BLOOD, 1995, 86 (06) : 2206 - 2212
[2] Helper-dependent adenoviral vectors mediate therapeutic factor VIII expression for several months with minimal accompanying toxicity in a canine model of severe hemophilia A
Brown, BD
Shi, CX
Powell, S
Hurlbut, D
Graham, FL
Lillicrap, D
[J]. BLOOD, 2004, 103 (03) : 804 - 810
[3] Therapeutic factor VIII levels and negligible toxicity in mouse and dog models of hemophilia A following gene therapy with high-capacity adenoviral vectors
Chuah, MKL
Schiedner, G
Thorrez, L
Brown, B
Johnston, M
Gillijns, V
Hertel, S
Van Rooijen, N
Lillicrap, D
Collen, D
VandenDriessche, T
Kochanek, S
[J]. BLOOD, 2003, 101 (05) : 1734 - 1743
[4] A gene-deleted adenoviral vector results in phenotypic correction of canine hemophilia B without liver toxicity or thrombocytopenia
Ehrhardt, A
Xu, H
Dillow, AM
Bellinger, DA
Nichols, TC
Kay, MA
[J]. BLOOD, 2003, 102 (07) : 2403 - 2411
[5] Germline alteration by gene therapy: assessing and reducing the risks
Gordon, JW
[J]. MOLECULAR MEDICINE TODAY, 1998, 4 (11): : 468 - 470
[6] Gene therapy for hemophilia: an imperative to succeed
Hough, C
Lillicrap, D
[J]. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2005, 3 (06) : 1195 - 1205
[7] Aberrant splicing and premature termination of transcription of the FVIII gene as a cause of severe canine hemophilia A: Similarities with the intron 22 inversion mutation in human hemophilia
Hough, C
Kamisue, S
Cameron, C
Notley, C
Tinlin, S
Giles, A
Lillicrap, D
[J]. THROMBOSIS AND HAEMOSTASIS, 2002, 87 (04) : 659 - 665
[8] Factor VIII alloantibodies in hemophilia
Jacquemin, MG
Saint-Remy, JMR
[J]. CURRENT OPINION IN HEMATOLOGY, 2004, 11 (03) : 146 - 150
[9] The Chapel Hill hemophilia A dog colony exhibits a factor VIII gene inversion
Lozier, JN
Dutra, A
Pak, E
Zhou, N
Zheng, ZL
Nichols, TC
Bellinger, DA
Read, M
Morgan, RA
[J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2002, 99 (20) : 12991 - 12996
[10] Helper-dependent adenoviral gene therapy mediates long-term correction of the clotting defect in the canine hemophilia A model
McCormack, W. M.
Seiler, M. P.
Bertin, T. K.
Ubhayakar, K.
Palmer, D. J. .
Ng, P.
Nichols, T. C.
Lee, B.
[J]. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2006, 4 (06) : 1218 - 1225

← 1 2 →